Cargando…

Immunovirotherapy for Pediatric Solid Tumors: A Promising Treatment That is Becoming a Reality

Immunotherapy has seen tremendous strides in the last decade, acquiring a prominent position at the forefront of cancer treatment since it has been proven to be efficacious for a wide variety of tumors. Nevertheless, while immunotherapy has changed the paradigm of adult tumor treatment, this progres...

Descripción completa

Detalles Bibliográficos
Autores principales: de la Nava, Daniel, Selvi, Kadir Mert, Alonso, Marta M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043602/
https://www.ncbi.nlm.nih.gov/pubmed/35493490
http://dx.doi.org/10.3389/fimmu.2022.866892
_version_ 1784694918685392896
author de la Nava, Daniel
Selvi, Kadir Mert
Alonso, Marta M.
author_facet de la Nava, Daniel
Selvi, Kadir Mert
Alonso, Marta M.
author_sort de la Nava, Daniel
collection PubMed
description Immunotherapy has seen tremendous strides in the last decade, acquiring a prominent position at the forefront of cancer treatment since it has been proven to be efficacious for a wide variety of tumors. Nevertheless, while immunotherapy has changed the paradigm of adult tumor treatment, this progress has not yet been translated to the pediatric solid tumor population. For this reason, alternative curative therapies are urgently needed for the most aggressive pediatric tumors. In recent years, oncolytic virotherapy has consolidated as a feasible strategy for cancer treatment, not only for its tumor-specific effects and safety profile but also for its capacity to trigger an antitumor immune response. This review will summarize the current status of immunovirotherapy to treat cancer, focusing on pediatric solid malignancies. We will revisit previous basic, translational, and clinical research and discuss advances in overcoming the existing barriers and limitations to translate this promising therapeutic as an every-day cancer treatment for the pediatric and young adult populations.
format Online
Article
Text
id pubmed-9043602
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90436022022-04-28 Immunovirotherapy for Pediatric Solid Tumors: A Promising Treatment That is Becoming a Reality de la Nava, Daniel Selvi, Kadir Mert Alonso, Marta M. Front Immunol Immunology Immunotherapy has seen tremendous strides in the last decade, acquiring a prominent position at the forefront of cancer treatment since it has been proven to be efficacious for a wide variety of tumors. Nevertheless, while immunotherapy has changed the paradigm of adult tumor treatment, this progress has not yet been translated to the pediatric solid tumor population. For this reason, alternative curative therapies are urgently needed for the most aggressive pediatric tumors. In recent years, oncolytic virotherapy has consolidated as a feasible strategy for cancer treatment, not only for its tumor-specific effects and safety profile but also for its capacity to trigger an antitumor immune response. This review will summarize the current status of immunovirotherapy to treat cancer, focusing on pediatric solid malignancies. We will revisit previous basic, translational, and clinical research and discuss advances in overcoming the existing barriers and limitations to translate this promising therapeutic as an every-day cancer treatment for the pediatric and young adult populations. Frontiers Media S.A. 2022-04-13 /pmc/articles/PMC9043602/ /pubmed/35493490 http://dx.doi.org/10.3389/fimmu.2022.866892 Text en Copyright © 2022 de la Nava, Selvi and Alonso https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
de la Nava, Daniel
Selvi, Kadir Mert
Alonso, Marta M.
Immunovirotherapy for Pediatric Solid Tumors: A Promising Treatment That is Becoming a Reality
title Immunovirotherapy for Pediatric Solid Tumors: A Promising Treatment That is Becoming a Reality
title_full Immunovirotherapy for Pediatric Solid Tumors: A Promising Treatment That is Becoming a Reality
title_fullStr Immunovirotherapy for Pediatric Solid Tumors: A Promising Treatment That is Becoming a Reality
title_full_unstemmed Immunovirotherapy for Pediatric Solid Tumors: A Promising Treatment That is Becoming a Reality
title_short Immunovirotherapy for Pediatric Solid Tumors: A Promising Treatment That is Becoming a Reality
title_sort immunovirotherapy for pediatric solid tumors: a promising treatment that is becoming a reality
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043602/
https://www.ncbi.nlm.nih.gov/pubmed/35493490
http://dx.doi.org/10.3389/fimmu.2022.866892
work_keys_str_mv AT delanavadaniel immunovirotherapyforpediatricsolidtumorsapromisingtreatmentthatisbecomingareality
AT selvikadirmert immunovirotherapyforpediatricsolidtumorsapromisingtreatmentthatisbecomingareality
AT alonsomartam immunovirotherapyforpediatricsolidtumorsapromisingtreatmentthatisbecomingareality